Affordability and Access Options for Patients
Helsinn Cares offers valuable patient programs to help support the affordability of and access to AKYNZEO®. Depending on the patient’s eligibility, resources may be available to reduce patient costs for AKYNZEO®.
Programs available for patients are described below. One or more may be right for your patients:
Pay $0 for AKYNZEO® With the Pay $0 Savings Program*
With the AKYNZEO® Pay $0 Savings Program:
*Restrictions apply. Not available to patients enrolled in state or federal healthcare programs, including Medicare, Medicaid, Medigap, VA, DoD or TRICARE.
Eligibility Criteria: Good toward the purchase of AKYNZEO® prescriptions. No substitutions permitted. Save this card to reuse with each prescription. Not available to patients enrolled in state or federal healthcare programs, including Medicare, Medicaid, Medigap, VA, DoD or TRICARE. Offer available to MA residents through June 30, 2019. For all other patients, this offer will expire October 3, 2019. May not be combined with any other coupon, discount, prescription savings card, free trial or other offer. Federal law prohibits the selling, purchasing, trading, or counterfeiting of this card. Such activities may result in imprisonment of 10 years, fines up to $25,000, or both. Void outside the USA and where prohibited by law. Helsinn Therapeutics (U.S.), Inc. reserves the right to rescind, revoke, or amend this offer at any time without notice. Patients and pharmacies are responsible for disclosing to insurance carriers the redemption and value of the card and complying with any other conditions imposed by insurance carriers on third party payers. The value of this card is not contingent on any prior or future purchases. The card is solely intended to provide savings on any purchase of AKYNZEO®. Use of the card for any one purchase does not obligate the patient to make future purchases of AKYNZEO® or any other product.
Helsinn Cares Patient Assistance Program
Enrollment in Helsinn Cares is required to assess the eligibility for the Patient Assistance Program.
Helsinn Cares Patient Assistance Program has been specifically designed for patients who need assistance paying for AKYNZEO®.
AKYNZEO is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. AKYNZEO is an oral fixed combination of palonosetron and netupitant: palonosetron prevents nausea and vomiting during the acute phase and netupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy.1
Important Safety Information
Warnings and Precautions
Use in Specific Populations
For more information about AKYNZEO, please see Full Prescribing Information.
To report SUSPECTED ADVERSE REACTIONS, contact Helsinn at 1-855-541-3498 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
1. AKYNZEO® (netupitant/palonosetron) capsules. Full Prescribing Information.
AKYNZEO® is a registered trademark of Helsinn Healthcare SA, Switzerland, used under license.